Clopidogrel News and Research

RSS

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Prasugrel reduces cardiovascular events among patients managed medically for ACS

A study has found that the anti-clotting medication prasugrel reduced cardiovascular events among patients who present with an acute coronary syndrome and are managed medically after an angiogram is performed to determine coronary anatomy.

25 Oct 2012

Reduced copayment policy has benefits all round

Reducing patients’ copayments for statins and clopidogrel could increase their adherence without adding financial burden to the healthcare system, researchers say.

18 Oct 2012

Reduced copayment policy has benefits all round

Reducing patients’ copayments for statins and clopidogrel could increase their adherence without adding financial burden to the healthcare system, researchers say.

11 Oct 2012

Older adults do not tend to adhere to their prescribed drugs after heart attack

Older adults who have had a heart attack don't tend to adhere to their prescribed drugs according to a new study of Medicare beneficiaries by the University of Maryland School of Pharmacy.

11 Oct 2012

PLATO: Causes of lower mortality with ticagrelor identified

The mortality reduction with ticagrelor versus clopidogrel is due to fewer deaths from cardiovascular, bleeding, and infection complications, say researchers.

1 Oct 2012

WOEST: Dual antiplatelet therapy more effective than triple

Dual antiplatelet therapy with clopidogrel and an oral anticoagulant reduces bleeding and mortality more effectively than triple therapy including aspirin, researchers say.

6 Sep 2012

MADONNA: Personalized antiplatelet therapy savior for angioplasty patients?

Personalized antiplatelet treatment may improve cardiac outcomes after percutaneous coronary intervention, researchers suggest.

4 Sep 2012

Combination of POZEN’s PA32540 and clopidogrel results in greater antiplatelet effects

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).

30 Aug 2012

AstraZeneca’s ticagrelor receives Class I recommendation from ESC

AstraZeneca today announced that ticagrelor, an oral antiplatelet medicine, received a Class I recommendation from the European Society of Cardiology (ESC) in the revised "Guidelines on the Management of Acute Myocardial Infarction in Patients Presenting with Persistent ST-Segment Elevation (STEMI)" guidelines.

29 Aug 2012

Omitting aspirin leads to less bleedings but does not increase risk of stent thrombosis, MI

Lifelong anticoagulation is necessary for the prevention of stroke in patients with rhythm disturbances and with mechanical valves. Patients who have a coronary stent implanted also need the antiplatelet drugs aspirin and clopidogrel to prevent the rare but lethal complication of stent thrombosis.

29 Aug 2012

Taking aspirin associated with reduced risk of death from prostate cancer

Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, says a new study that includes a researcher at UT Southwestern Medical Center.

29 Aug 2012

Global platelet reactivity effectively identifies ACS patients at high risk of ischemic events

Global platelet reactivity is more effective than responsiveness to clopidogrel in identifying acute coronary syndrome (ACS) patients at high risk of ischemic events, according to research presented at the ESC Congress today. The results from the RECLOSE 2-ACS study were presented by Dr Rossella Marcucci from Italy.

28 Aug 2012

Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI

Personalized antiplatelet treatment leads to better outcomes than standard antiplatelet treatment in patients undergoing coronary stent implantation, according to results from the MADONNA study presented at ESC Congress 2012.

28 Aug 2012

Study explores gender-related differences in patients hospitalized for acute heart failure

Women with acute heart failure have similar in-hospital mortality to men but are less treated in the real world, according to results from the global ALARM-HF registry presented today at the ESC Congress 2012. The findings were presented by Dr John T. Parissis from Greece.

27 Aug 2012

Prasugrel as safe as clopidogrel in preventing heart attack, stroke and death

The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs - prasugrel and clopidogrel - in preventing the first occurrence of death, heart attack or stroke, according to Duke University Medical Center cardiologists.

27 Aug 2012